磷酸化
沃特曼宁
激酶
磷酸丝氨酸
生物
丝氨酸
DNA损伤
分子生物学
磷酸化级联
蛋白质磷酸化
癌症研究
细胞生物学
蛋白激酶A
DNA
生物化学
蛋白激酶B
作者
Giovanna L.M. Damia,Laura Filiberti,Faina Vikhanskaya,Laura Carrassa,Yoichi Taya,Maurizio D’Incalci,Massimo Broggini
出处
期刊:Neoplasia
[Elsevier BV]
日期:2001-01-01
卷期号:3 (1): 10-16
被引量:114
标识
DOI:10.1038/sj.neo.7900122
摘要
Posttranslational modifications of p53 induced by two widely used anticancer agents, cisplatinum (DDP) and taxol were investigated in two human cancer cell lines. Although both drugs were able to induce phosphorylation at serine 20 (Ser20), only DDP treatment induced p53 phosphorylation at serine 15 (Ser15). Moreover, both drug treatments were able to increase p53 levels and consequently the transcription of waf1 and mdm-2 genes, although DDP treatment resulted in a stronger inducer of both genes. Using two ataxia telangiectasia mutated (ATM) cell lines, the role of ATM in drug-induced p53 phosphorylations was investigated. No differences in drug-induced p53 phosphorylation could be observed, indicating that ATM is not the kinase involved in these phosphorylation events. In addition, inhibition of DNA-dependent protein kinase activity by wortmannin did not abolish p53 phosphorylation at Ser15 and Ser20, again indicating that DNA-PK is unlikely to be the kinase involved. After both taxol and DDP treatments, an activation of hCHK2 was found and this is likely to be responsible for phosphorylation at Ser20. In contrast, only DDP was able to activate ATR, which is the candidate kinase for phosphorylation of Ser15 by this drug. This data clearly suggests that differential mechanisms are involved in phosphorylation and activation of p53 depending on the drug type.
科研通智能强力驱动
Strongly Powered by AbleSci AI